Expansion Of Access To MenB Vaccine Urgently Needed

Published: Tue 15 Nov 2022 07:42 AM
Meningococcal B is a rare but very serious disease, causing death and serious long-term disabilities. Even when the disease is identified and treated early, one to two people out of every 10 may die. One to two people out of every 10 who survive meningococcal disease can have long-term complications: extensive skin scarring, limb amputation, hearing loss, seizures, or brain injury.
Pharmac is currently considering expanding access to meningococcal B vaccine. Immunisation Advisory Centre Medical Director Nikki Turner says "this is a very nasty and frightening disease that particularly affects our young children and infants. There is a good vaccine that can be used, but up until now it has not been widely available unless you privately purchase it, which many of our families cannot afford.
"We are very pleased to see Pharmac is consulting on expanding access to the MenB vaccine, Bexsero. We strongly support the introduction of this on the national schedule programme, particularly for our infants and children aged under 5 years," says Nikki Turner.
IMAC has provided our view on this to Pharmac.

Next in Lifestyle

Local Playwright Casts A Spell Over Hamilton
By: Melanie Allison
New $12M Wellness & Diagnostic Centre Opens In Hamilton ‘Disrupting The Historic Continuum’ For Māori
By: Te Kohao Health
Fresh NZ-grown Vegetables Now Even Better Value For Cash Strapped Kiwis
By: Vegetables New Zealand
Supporting The Next Generation To Succeed In Agriculture And Horticulture
By: AgriFutures
New Crops, Conversations And Illuminations: Asian Aotearoa Arts 2024 Full Programme Announcement
By: Asian Aotearoa Arts
Accessing The Benefits Of Music Therapy
By: Arts Access Aotearoa
View as: DESKTOP | MOBILE © Scoop Media